These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 11400948)

  • 21. Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease.
    Carnevale-Schianca F; Martin P; Sullivan K; Flowers M; Gooley T; Anasetti C; Deeg J; Furlong T; McSweeney P; Storb R; Nash RA
    Biol Blood Marrow Transplant; 2000; 6(6):613-20. PubMed ID: 11128811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease.
    Jurado M; Vallejo C; Pérez-Simón JA; Brunet S; Ferra C; Balsalobre P; Pérez-Oteyza J; Espigado I; Romero A; Caballero D; Sierra J; Ribera JM; Díez JL
    Biol Blood Marrow Transplant; 2007 Jun; 13(6):701-6. PubMed ID: 17531780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amelioration of steroid-resistant chronic graft-versus-host-mediated liver disease via tacrolimus treatment.
    Nagler A; Menachem Y; Ilan Y
    J Hematother Stem Cell Res; 2001 Jun; 10(3):411-7. PubMed ID: 11454316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic graft-versus-host disease: Pathogenesis and clinical management.
    Pérez-Simón JA; Sánchez-Abarca I; Díez-Campelo M; Caballero D; San Miguel J
    Drugs; 2006; 66(8):1041-57. PubMed ID: 16789791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Do corticosteroids add any benefit to standard GVHD prophylaxis in allogeneic BMT?
    Ancín I; Ferrá C; Gallardo D; Peris J; Berlanga J; Gonzalez JR; Virgili N; Grañena A
    Bone Marrow Transplant; 2001 Jul; 28(1):39-45. PubMed ID: 11498742
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Randomized study comparing corticosteroids and cyclosporine.
    Kennedy MS; Deeg HJ; Storb R; Doney K; Sullivan KM; Witherspoon RP; Appelbaum FR; Stewart P; Sanders J; Buckner CD
    Am J Med; 1985 Jun; 78(6 Pt 1):978-83. PubMed ID: 3893112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Continuous infusion cyclosporine and nifedipine to day +100 with short methotrexate and steroids as GVHD prophylaxis in unrelated donor transplants.
    Liesveld J; Duerst R; Rapoport A; Constine L; Abboud C; Packman C; Wedow L; Zwetsch L; McKenna B; Linder T; Silverman W; Swift S; Rowe J; DiPersio J
    Bone Marrow Transplant; 1999 Sep; 24(5):511-6. PubMed ID: 10482935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk and prognostic factors for Japanese patients with chronic graft-versus-host disease after bone marrow transplantation.
    Atsuta Y; Suzuki R; Yamamoto K; Terakura S; Iida H; Kohno A; Naoe T; Yano K; Wakita A; Taji H; Hamaguchi M; Kodera Y; Sao H; Morishima Y; Hamajima N; Morishita Y
    Bone Marrow Transplant; 2006 Feb; 37(3):289-96. PubMed ID: 16400341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children.
    Rovelli A; Arrigo C; Nesi F; Balduzzi A; Nicolini B; Locasciulli A; Vassallo E; Miniero R; Uderzo C
    Bone Marrow Transplant; 1998 Mar; 21(6):577-81. PubMed ID: 9543061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.
    Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CXCL9 Predicts Severity at the Onset of Chronic Graft-versus-host Disease.
    Giesen N; Schwarzbich MA; Dischinger K; Becker N; Hummel M; Benner A; Radujkovic A; Müller-Tidow C; Dreger P; Luft T
    Transplantation; 2020 Nov; 104(11):2354-2359. PubMed ID: 31929430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to thalidomide therapy in refractory chronic graft-versus-host disease.
    Browne PV; Weisdorf DJ; DeFor T; Miller WJ; Davies SM; Filipovich A; McGlave PB; Ramsay NK; Wagner J; Enright H
    Bone Marrow Transplant; 2000 Oct; 26(8):865-9. PubMed ID: 11081386
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease.
    Herrera AF; Kim HT; Bindra B; Jones KT; Alyea EP; Armand P; Cutler CS; Ho VT; Nikiforow S; Blazar BR; Ritz J; Antin JH; Soiffer RJ; Koreth J
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1737-43. PubMed ID: 25017765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thalidomide for treatment of graft-versus-host disease.
    Vogelsang GB; Hess AD; Santos GW
    Bone Marrow Transplant; 1988 Sep; 3(5):393-8. PubMed ID: 3056547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease.
    Johnston LJ; Brown J; Shizuru JA; Stockerl-Goldstein KE; Stuart MJ; Blume KG; Negrin RS; Chao NJ
    Biol Blood Marrow Transplant; 2005 Jan; 11(1):47-55. PubMed ID: 15625544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation.
    Pavletic SZ; Smith LM; Bishop MR; Lynch JC; Tarantolo SR; Vose JM; Bierman PJ; Hadi A; Armitage JO; Kessinger A
    Am J Hematol; 2005 Apr; 78(4):265-74. PubMed ID: 15795914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
    Pérez-Simón JA; Martino R; Caballero D; Valcarcel D; Rebollo N; de la Cámara R; de Oteiza JP; Heras I; Calvo MV; Sierra J; San Miguel JF;
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):664-71. PubMed ID: 18489992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A three or more drug combination as effective therapy for moderate or severe chronic graft-versus-host disease.
    Gaziev D; Lucarelli G; Polchi P; Angelucci E; Galimberti M; Giardini C; Baronciani D; Erer B; Sodani P
    Bone Marrow Transplant; 2001 Jan; 27(1):45-51. PubMed ID: 11244437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB).
    Arora M; Nagaraj S; Wagner JE; Barker JN; Brunstein CG; Burns LJ; Defor TE; McMillan ML; Miller JS; Weisdorf DJ
    Biol Blood Marrow Transplant; 2007 Oct; 13(10):1145-52. PubMed ID: 17889350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.